[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"seborrheic-dermatitis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:seborrheic-dermatitis":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,43,69,103],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100624007","phase-1-zyg24002-lotion-to-evaluate-the-safety-tolerability-pharmacokinetics-and-preliminary-efficacy-in-adult-patients-with-mild-to-moderate-seborrheic-dermatitis-100624007",false,"NCT07404033","ZYG24002 Lotion to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy in Adult Patients With Mild to Moderate Seborrheic Dermatitis","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Ⅰb Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Different Concentrations of ZYG24002 Lotion in Adult Patients With Mild to Moderate Seborrheic Dermatitis","Inclusion Criteria:\n\n1. Aged 18 (inclusive) to 65 (inclusive) years, of either sex. Male subjects must have no childbearing potential or agree to adopt contraceptive measures until 3 months after the end of the study; female subjects of childbearing potential must be non-pregnant and non-lactating, and adopt reliable contraceptive measures during the study period and within 3 months after the last dose.\n2. Diagnosed with seborrheic dermatitis by a dermatologist (diagnostic criteria refer to the Expert Consensus on Integrated Traditional Chinese and Western Medicine Diagnosis and Treatment of Seborrheic Dermatitis (2024 Edition) and the 2015 Asian Consensus on Seborrheic Dermatitis), with a disease duration of ≥ 3 months; baseline Investigator's Global Assessment for Seborrheic Dermatitis (IGA-SD) score (0-4 point scale) of 2 (mild) or 3 (moderate); at baseline, the overall scores for erythema and scaling are at least mild severity (score 1) respectively. The involved body surface area (BSA%) is ≤ 10%, and skin lesions are distributed in at least two anatomical sites such as the scalp, face, and trunk.\n3. No obvious signs of infection at the test site (e.g., pustules, crusts caused by bacterial infection). The subject is in good general skin condition at enrollment, with no other active skin lesions that may interfere with the clinical assessment.\n4. Has not participated in any other clinical trials or used any investigational drugs within the past 3 months.\n5. Study participants provide informed consent to participate in this study, sign the informed consent form (ICF), are able to understand the study requirements, and are willing to complete all scheduled visits and examinations in accordance with the investigator's instructions.\n\nExclusion Criteria:\n\n1. Severe active seborrheic dermatitis: IGA-SD score of 4 points or extensive skin lesions (BSA \\> 10%), accompanied by obvious exudation and infection, requiring systemic therapy. Participants whose disease activity is deemed unsuitable for study enrollment by the investigator (including but not limited to situations where 4 weeks of placebo-only treatment may lead to unacceptable disease progression).\n2. Comorbidities of other skin diseases that may interfere with study assessments, such as psoriasis, severe acne, rosacea, atopic dermatitis, etc., which would confound the observation of seborrheic dermatitis lesions.\n3. Administration of systemic glucocorticoids, systemic retinoids, immunosuppressants, oral\u002Fintravenous antifungals, phototherapy, PDE-4 inhibitors, or JAK inhibitors within 4 weeks; topical glucocorticoids, calcineurin inhibitors, PDE-4 inhibitors, antifungals, retinoids, keratolytics, selenium\u002Ftar-containing preparations on the study area within 2 weeks; any biologic agents within 6 months; or potent CYP3A4 inhibitors\u002Finducers within 4 weeks.\n4. Receipt of physical or chemical cosmetic treatments on the head and face within the past month (e.g., intense pulsed light, glycolic acid peels), resulting in temporary skin barrier dysfunction that has not yet recovered to normal.\n5. A history of known severe hypersensitivity or severe adverse reactions to ZYG24002 or its excipients.\n6. Comorbidities of other skin diseases that may increase the systemic absorption of ZYG24002, such as Netherton syndrome or erythroderma.\n7. Current use of immunosuppressants or diagnosis of immune deficiency.\n8. A history of malignancy within 5 years prior to screening or at screening.\n9. Poorly controlled chronic diseases, including but not limited to endocrine disorders (e.g., diabetes mellitus with significantly elevated fasting blood glucose and obvious clinical symptoms, hyperthyroidism); a history of severe cardiovascular and cerebrovascular diseases (e.g., myocardial infarction, stroke); active peptic ulcers or chronic inflammatory bowel disease, etc.\n10. Abnormal liver function: ALT or AST \\> 2 × upper limit of normal (ULN), or total bilirubin \\> 1.5 × ULN at screening; abnormal renal function: serum creatinine \\> 1.5 × ULN; or other clinically significant abnormal laboratory findings that are deemed unsuitable for enrollment by the investigator.\n11. Human immunodeficiency virus (HIV) infection; active hepatitis C virus (HCV) infection (anti-HCV positive); active hepatitis B virus (HBV) infection (HBV-DNA \\> 2000 IU\u002FmL or 10⁴ CPs\u002FmL); or positive treponema pallidum antibody with evidence of active infection.\n12. Diagnosis of psychiatric or neurological disorders that may affect compliance or increase study-related risks.\n13. Pregnancy, lactation, or planned pregnancy; female subjects of childbearing potential who have not initiated reliable contraceptive measures at least 30 days prior to the first dose and who cannot commit to maintaining such measures for 3 months after the last dose.\n14. Diagnosis of alcohol or addictive substance dependence within the past 12 months, or other conditions that the investigator believes may compromise study compliance.\n15. Any other conditions that the investigator deems may interfere with study results or pose an unacceptable safety risk to the participant.","ALL","18 Years","65 Years",{"count":20,"type":21},48,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group Phase Ib clinical trial conducted in adult patients with mild to moderate seborrheic dermatitis (IGA-SD score of 2-3 points). The study aims to evaluate the safety, tolerability, and steady-state pharmacokinetic (PK) profiles of three concentrations (0.5%, 0.75%, and 1.0%) of ZYG24002 Lotion following continuous topical application once daily (QD) or twice daily (BID) for 28 days, and to conduct a preliminary exploration of the drug's efficacy.",[27],"Seborrheic Dermatitis",[29],"seborrheic dermatitis","RECRUITING","2026-06-16",{"date":33,"type":34},"2026-06-17","ACTUAL",{"date":36,"type":34},"2026-04-24",{"date":38,"type":21},"2026-12-31",{"name":40,"class":41},"Sinomune Pharmaceutical Co., Ltd","INDUSTRY",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":49,"sex":50,"minAge":17,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":42},"100642448","a-study-on-scalp-health-and-integrated-scalp-management-protocols-for-hair-transplant-patients-100642448","NCT07641686","A Study on Scalp Health and Integrated Scalp Management Protocols for Hair Transplant Patients","Inclusion Criteria:\n\n1. Healthy Chinese male subjects aged between 18 and 55 years old;\n2. Diagnosed with androgenetic alopecia, with alopecia grade from Grade II to Grade VI per Hamilton-Norwood classification;\n3. Scheduled to receive hair transplantation; scalp condition is confirmed suitable for trial participation by dermatologist assessment after hair graft surgery;\n4. With or without mild-to-moderate scalp seborrheic dermatitis (SD score ranging from 0 to 9);\n5. No anti-dandruff shampoo used within the latest 14 days prior to enrollment;\n6. No hair dyeing, perming or hair styling cosmetic treatments in the past 30 days;\n7. Able to comply with all scheduled study visits;\n8. Possess normal communication and comprehension capacity;\n9. Agree to regular follow-up visits and complete related questionnaires on time;\n10. Fully understand trial procedures, volunteer to join the study and provide written informed consent.\n\nExclusion Criteria:\n\n1. Suffering from severe scalp seborrheic dermatitis;\n2. Received oral or topical antifungal drugs, glucocorticoids or other therapeutic medicines for seborrheic dermatitis within the preceding 30 days;\n3. Complicated with other scalp diseases (such as psoriasis), or with obvious infection or unhealed wounds on the target treatment area;\n4. Known hypersensitivity to ingredients including selenium disulfide, salicylic acid and related components;\n5. History of autoimmune diseases or severe organic diseases involving heart, brain, lung, liver, kidney and other vital organs;\n6. Past medical history of psychiatric or psychological disorders;\n7. Refuse to sign the written informed consent form;\n8. Currently enrolled in another interventional clinical trial;\n9. Diagnosed with alopecia areata, pseudopelade, cicatricial alopecia or other scalp and hair disorders;\n10. Have taken part in any other clinical trial within the prior 3 months;\n11. Judged as inappropriate for trial participation based on investigator's clinical assessment.",true,"MALE","55 Years",{"count":53,"type":21},120,[55],"NA","A total of 120 Chinese male subjects aged 18-50 years who have undergone hair transplantation are planned to be enrolled in this study. Among them, 90 participants with mild-to-moderate scalp seborrheic dermatitis (hereinafter abbreviated as SD) will be stratified and randomly allocated into two groups based on a randomization table with stratification factors including SD severity grading, alopecia classification and age. Subjects in the test product group (hereinafter referred to as the holistic group) will use the test shampoo plus basic shampoo, while those in the basic control group will receive only basic shampoo. The remaining 30 non-SD subjects will constitute the non-SD control group and use basic shampoo alone.\n\n1. Primary Objective To compare pre- and post-treatment changes in clinical, physiological, biological and microecological parameters related to SD manifestations, scalp health and skin barrier repair (including transepidermal water loss, scalp hydration, scalp sebum content, etc.) between the holistic group receiving the investigational shampoo regimen and the basic control group via non-invasive instrumental measurement, clinical assessment, clinical photography and subject self-evaluation. The safety and efficacy of the test product in improving scalp condition and skin barrier function will be evaluated, and its potential underlying mechanisms will be explored.\n2. Secondary Objective To investigate the impacts of the test product versus the control shampoo on hair transplant-associated complications (e.g., folliculitis), wound healing, follicular shedding phase, graft survival rate and hair growth parameters among SD patients.\n3. Exploratory Objective To collect baseline clinical, physiological, biological and scalp microecological data from non-SD recipients after hair transplantation for reference purposes.",[58,27,59],"Hair Transplantation","Scalp Care","2026-06-08",{"date":62,"type":34},"2026-06-11",{"date":64,"type":34},"2025-02-21",{"date":66,"type":21},"2027-12-30",{"name":68,"class":41},"ChinaNorm",{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":49,"sex":16,"minAge":76,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":22,"phases":79,"briefSummary":80,"conditions":81,"keywords":86,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":4},"100635218","sebum-metabolomics-and-lipidomics-for-clinical-applications-100635218","NCT07549828","Sebum Metabolomics and Lipidomics for Clinical Applications","Development of a Sample Collection Protocol and a Metabolomics\u002FLipidomics Analytical Strategy for Investigating Sebum and Its Clinical Applications","A. Healthy Participants\n\nInclusion Criteria:\n\n* Individuals aged ≥20 years, regardless of sex or ethnicity, and assessed by the investigator to be in good health and suitable for participation.\n* No diagnosed skin diseases or chronic systemic diseases.\n* No use of medications or receipt of dermatological treatments that may affect sebum secretion or the skin microbiome within the past two weeks.\n\nExclusion Criteria:\n\n* Known allergy to Sebutape or similar adhesive tapes, or a history of related adverse reactions.\n* Presence of acute or chronic skin diseases, or chronic systemic diseases.\n* Use of medications or receipt of dermatological treatments that may affect sebum secretion or the skin microbiome within the past two weeks.\n* Use of lotions, sunscreen, or other skincare products that may affect skin condition within 12 hours prior to sampling.\n* Any other conditions deemed unsuitable for participation by the principal investigator.\n\nB. Participants with Skin Diseases or Specific Skin Conditions\n\nInclusion Criteria:\n\n* Individuals aged ≥20 years, regardless of sex or ethnicity, and assessed by the investigator to be suitable for participation.\n* Diagnosed by a physician or clinically assessed as having one of the following:\n\n  * Acne\n  * Atopic dermatitis\n  * Seborrheic dermatitis\n  * Psoriasis\n  * Other common skin diseases\n  * Specific skin conditions (e.g., postmenopausal or aging-related skin changes)\n\nExclusion Criteria:\n\n* Known allergy to Sebutape or similar adhesive tapes, or a history of related adverse reactions.\n* Severe disease that may compromise skin integrity or pose a risk to participant safety.\n* Use of lotions, sunscreen, or other skincare products that may affect skin condition within 12 hours prior to sampling.\n* Any other conditions deemed unsuitable for participation by the principal investigator.\n\nC. Participants Receiving Dermatological Treatments or Using Skincare Products\n\nInclusion Criteria:\n\n* Individuals aged ≥20 years, regardless of sex or ethnicity, and assessed by the investigator to be suitable for participation.\n* Participants who, based on clinical needs or daily routines, are currently using or are expected to use or receive any of the following:\n\n  * Physician-prescribed topical dermatological medications\n  * Physician-prescribed systemic therapies (oral or injectable)\n  * Routine use of general skincare products\n  * Physician-directed non-invasive dermatological treatments\n\nExclusion Criteria:\n\n* Known allergy to Sebutape or similar adhesive tapes, or a history of related adverse reactions.\n* Severe disease that may compromise skin integrity or pose a risk to participant safety.\n* Use of lotions, sunscreen, or other skincare products that may affect skin condition within 12 hours prior to sampling.\n* Any other conditions deemed unsuitable for participation by the principal investigator.\n\nD. Healthy Participants Undergoing Short-term Antibiotic Intervention\n\nInclusion Criteria:\n\n* Individuals aged ≥20 years, regardless of sex or ethnicity.\n* Assessed by the investigator to be healthy, with skin condition suitable for the intervention used in this study.\n\nExclusion Criteria:\n\n* Known allergy to Sebutape or similar adhesive tapes, or a history of related adverse reactions.\n* Known allergy or adverse reactions to the study intervention drug (topical antibiotic ointment containing bacitracin, polymyxin B, and neomycin).\n* Presence of visible skin disease, wounds, infection, inflammation, or other abnormal skin conditions at the sampling site.\n* Use of lotions, sunscreen, or other skincare products that may affect skin condition within 12 hours prior to sampling.\n* Any other conditions deemed unsuitable for participation by the principal investigator.","20 Years",{"count":78,"type":21},200,[55],"This study aims to develop a standardized workflow for sebum sampling and metabolomics\u002Flipidomics analysis using Sebutape. A total of 200 participants will be recruited, including healthy individuals, patients with skin diseases, individuals undergoing dermatological treatments or using skincare products, and a subset of healthy participants receiving short-term topical antibiotic intervention. The study will investigate sebum composition, skin microbiome profiles, and their interactions under different conditions to explore potential biomarkers and clinical applications.",[82,83,27,84,85],"Acne","Atopic Dermatitis","Psoriasis","Healthy Subjects (HS)",[87,88,89,90,91,92],"Sebum","Lipidomics","Metabolomics","Skin microbiome","Sebutape","LC-MS\u002FMS","NOT_YET_RECRUITING","2026-04-17",{"date":36,"type":34},{"date":97,"type":21},"2026-04-01",{"date":99,"type":21},"2029-03-31",{"name":101,"class":102},"National Taiwan University Hospital","OTHER",{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":49,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":22,"phases":111,"briefSummary":112,"conditions":113,"keywords":116,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":42},"100511654","the-use-of-image-based-computer-gradings-in-the-analysis-of-acne-rosacea-melasma-and-seborrheic-dermatitis-100511654","NCT05942248","The Use of Image-Based Computer Gradings in the Analysis of Acne, Rosacea, Melasma, and Seborrheic Dermatitis","Inclusion Criteria:\n\n* Adults with acne, rosacea, melasma or seborrheic dermatitis\n\nExclusion Criteria:\n\n* Prisoners\n* Adults unable to consent\n* Artificial facial markings on day of facial photography (such as piercings and tattoos) that may interfere with imaging in the opinion of the investigator",{"count":110,"type":21},150,[55],"The study is conducted to determine if image-based computer grading can of acne, melasma, rosacea and seborrheic dermatitis correlate well to expert based clinical severity grading.",[82,114,115,27],"Melasma","Rosacea",[117,118],"Artificial Intelligent","Skin","2024-08-26",{"date":121,"type":34},"2024-08-27",{"date":123,"type":34},"2023-06-06",{"date":125,"type":21},"2025-02-28",{"name":127,"class":41},"Integrative Skin Science and Research"]